Review
Published on 02 Feb 2023
Clofazimine for the treatment of tuberculosis
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1100488
- 13,025 views
- 27 citations
Type at least 3 characters
316 articles
Articles
Editorial
Published on 01 Feb 2023
Editorial: Cell cycle control as a new therapeutic approach for SARS-CoV-2 infection
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1136277
- 951 views
- 1 citation
Original Research
Published on 01 Feb 2023
Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1106044
- 2,639 views
- 8 citations
Editorial
Published on 26 Jan 2023
Editorial: New trends in natural product research for inflammatory and infectious diseases: Volume II
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1144074
- 1,394 views
- 1 citation
Mini Review
Published on 24 Jan 2023
Phages against killer superbugs: An enticing strategy against antibiotics-resistant pathogens
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1036051
- 6,675 views
- 9 citations
Original Research
Published on 17 Jan 2023
Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1107198
- 3,355 views
- 6 citations
Original Research
Published on 13 Jan 2023
Development and validation of two bioanalysis methods for the determination of etimicin in human serum and urine by liquid chromatography-tandem mass spectrometry: Applications to a human pharmacokinetic and breakpoint study
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1076046
- 1,858 views
- 3 citations
Systematic Review
Published on 09 Jan 2023
Activity of the genus Zanthoxylum against diseases caused by protozoa: A systematic review
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2022.873208
- 2,155 views
- 2 citations
Original Research
Published on 09 Jan 2023
Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1032674
- 3,223 views
- 8 citations
Opinion
Published on 05 Jan 2023
How and when does monkeypox (mpox) transmit: Implications for prevention and treatments
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1109928
- 2,697 views
- 3 citations
Original Research
Published on 04 Jan 2023
Successful establishment and five-year sustainability of a neonatal-specific antimicrobial stewardship program in a low middle-income country
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1076392
- 1,805 views
- 3 citations
Original Research
Published on 04 Jan 2023
Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1081123
- 3,145 views
- 4 citations
Original Research
Published on 20 Dec 2022
Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1072202
- 4,318 views
- 14 citations
Original Research
Published on 16 Dec 2022
Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2022.975066
- 4,590 views
- 10 citations
Original Research
Published on 13 Dec 2022
Cell cycle block by p53 activation reduces SARS-CoV-2 release in infected alveolar basal epithelial A549-hACE2 cells
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1018761
- 3,029 views
- 8 citations
Clinical Trial
Published on 12 Dec 2022
A randomized, double-blind, placebo-controlled phase I trial of inhalation treatment of recombinant TFF2-IFN protein: A multifunctional candidate for the treatment of COVID-19
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1063106
- 1,612 views
- 1 citation